A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) - CO40115

F. Hoffmann-La Roche AG0 个研究点目标入组 185 人开始时间: 2024年5月2日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Age >/= 18 years at the time of signing Informed Consent Form, ECOG Performance Status of 0 or 1, Metastatic or inoperable locally advanced breast cancer, Measurable disease (at least one target lesion) according to RECIST v1.1, Life expectancy >/= 3 months, as determined by the investigator, Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment

•Adverse events from prior anti-cancer therapy that have not resolved to Grade </= 1 or better with the exception of alopecia of any grade and Grade </= 2 peripheral neuropathy, Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently), Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases, History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted, Significant cardiovascular disease, History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death

发起方